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Abstract
Inflammatory neuropathies represent disabling human autoimmune disorders with considerable disease variability. Animal
models provide insights into defined aspects of their disease pathogenesis. Forkhead box P3 (FoxP3)+ regulatory T
lymphocytes (Treg) are anti-inflammatory cells that maintain immune tolerance and counteract tissue damage in a variety of
immune-mediated disorders. Dysfunction or a reduced frequency of Tregs have been associated with different human
autoimmune disorders. We here analyzed the functional relevance of Tregs in determining disease manifestation and
severity in murine models of autoimmune neuropathies. We took advantage of the DEREG mouse system allowing
depletion of Treg with high specificity as well as anti-CD25 directed antibodies to deplete Tregs in mice in actively induced
experimental autoimmune neuritis (EAN). Furthermore antibody-depletion was performed in an adoptive transfer model of
chronic neuritis. Early Treg depletion increased clinical EAN severity both in active and adoptive transfer chronic neuritis.
This was accompanied by increased proliferation of myelin specific T cells and histological signs of peripheral nerve
inflammation. Late stage Treg depletion after initial disease manifestation however did not exacerbate inflammatory
neuropathy symptoms further. We conclude that Tregs determine disease severity in experimental autoimmune
neuropathies during the initial priming phase, but have no major disease modifying function after disease manifestation.
Potential future therapeutic approaches targeting Tregs should thus be performed early in inflammatory neuropathies.
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Introduction
Inflammatory polyneuropathies constitute disabling disorders of
the peripheral nervous system (PNS) including acute and chronic
variants. The acute Guillain-Barre´ syndrome (GBS) features rapid
onset, monophasic PNS inflammation [1,2]. Experimental auto-
immune neuritis (EAN) induced with myelin protein peptides
serves as an animal model of the demyelinating GBS variant [3].
Animal models for the axonal variants have been generated by
immunization against ganglioside components of the axonal
membrane [4]. Chronic inflammatory demyelinating polyradi-
culo-neuropathy (CIDP) – the most common chronic inflamma-
tory neuropathy – presents with chronic progressive or relapsing
remitting sensory and motor impairments and features immune
cell infiltration of peripheral nerves [5–7]. Animal models
replicating the clinical and pathological hallmarks of chronic
inflammatory neuropathies are less well established compared to
models of acute neuritis. Mice of the autoimmune-prone non
obese diabetic (NOD) strain with deficiency in the costimulatory
molecules B7-2 [8] and intercellular adhesion molecule (ICAM)-1
[9] spontaneously develop chronic inflammation and demyelin-
ation of peripheral nerves and constitute potential animal models
of CIDP. Both GBS and CIDP feature considerable disease
variability and factors determining the severity and course of
inflammatory neuropathies remain unknown. Specifically, it is
poorly understood why PNS auto-inflammation remains acute
monophasic in some, but progresses chronically in other patients.
Regulatory T cells (Tregs) expressing the transcription factor
forkhead box protein 3 (FoxP3) are a naturally occuring anti-
inflammatory T cell subset that is indispensable for the mainte-
nance of self tolerance and immune homeostasis [10,11]. Lack of
functional Tregs causes fatal autoimmune diseases both in mice
and humans [12,13]. Furthermore, Treg dysfunction has been
associated with different human autoimmune disorders [10]. Most
FoxP3+ Tregs are CD4+ T cells expressing the interleukin-2 (IL-2)
receptor a-chain (CD25) at high levels. They can suppress the
activation, proliferation and effector functions of various effector
immune cells. Reduced levels or an impaired function of Tregs
have been described in human patients with GBS [14–16] and
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CIDP [17,18]. In corresponding animal models, Tregs are present
in the PNS during EAN [19] at reduced numbers [20] while their
number increases with treatments ameliorating EAN [21–23].
Apart from these descriptive data, it remains unknown whether
Tregs exert a functional role in the manifestation of inflammatory
neuropathies. We here demonstrate that Tregs determine the
disease severity and variability, but do not influence the conversion
to chronicity in rodent models of acute and chronic inflammatory
neuropathies.
Material and Methods
Active EAN in DEREG mice
Generation of mice expressing the human diphtheria toxin
(DTx) receptor under the control of the FoxP3 promotor (DEREG
mice) has been previously described [24]. The line was maintained
in heterozygous breeding at a conventional animal housing facility.
Animal experimentation was approved by the responsible state
authorities. Genotyping was performed by routine PCR from tail
biopsy DNA as described [24]. Active EAN was induced by
subcutaneous injection of 200 mg myelin protein zero peptide
spanning amino acids 180–199 (P0180–199) (JPT peptide technol-
ogies) emulsified in 100 ml complete Freund’s adjuvant (CFA)
(Difco) containing 1 mg/ml heat inactivated Mycobacterium
tuberculosis strain H37RA mixed with 100 ml PBS into the flanks.
Animals received intraperitoneal injections of 500 ng pertussis
toxin (PTx) (Sigma-Aldrich) dissolved in 100 ml sterile phosphate
buffered saline (PBS) on the day of immunization (day 0) and on
day 2 after immunization (day 2). To achieve Treg depletion, DTx
(Merck) was dissolved in 100 ml sterile PBS and applied
intraperitoneally on d3 and d4 at 50 mg/kg (1 mg per mouse).
Two independent experiments were performed including 4–6
animals per group respectively. A modified clinical EAN score [25]
was applied daily by a blinded investigator (A.Z.) to quantify
impairments: 0 no impairments, 1 reduced tone of the tail, 2 limp
tail, 3 absent righting reflex or clasping of the hind limbs, 4 gait
ataxia, 5 mild paraparesis, 6 moderate paraparesis, 7 severe
paraparesis or paraplegia, 8 tetraparesis, 9 moribund, 10 death
due to neuropathy. At the end of the observation period
electrophysiology was performed and animals were sacrificed by
cervical dislocation. Flow cytometry was performed from purified
splenocytes.
Active EAN in SJL mice
Animals were maintained at the central animal facility of the
Heinrich-Heine-University, Du¨sseldorf under specific pathogen
free conditions and transferred to conventional housing for
experimentation. Animal experimentation was approved by the
responsible state authorities (Landesamt fu¨r Natur, Umwelt und.
Verbraucherschutz Nordrhein-Westfalen) with the approval ref-
erence numbers 8.87–50.10.34.08.207 and 50.05-230-65/06.
Active EAN was induced by subcutaneous injection of 2,5 mg
lyophilized bovine peripheral nerve myelin (bPNM) as previously
described [26] emulsified in 200 ml CFA/PBS mixture together
with PTx injections on day 0 and 2 after immunization as
described above. Phenotyping was performed every second day by
a blinded investigator (S.C.) using the clinical EAN score described
above and hind limb grip strength measurement (see below). For
early Treg depletion, mice received intraperitoneal injections of
purified anti-mouse CD25 antibody (no azide, low endotoxin,
clone PC61, rat IgG1, BioLegend) at 0.125 mg/mouse/day on
day 4 to day 1 before immunization (day -4 to day -1). This clone
had been previously demonstrated to deplete Tregs [27]. Late
Treg depletion was performed by antibody injection on days 14 to
17 after immunization. Control mice received comparable
amounts of isotype control antibody (rat IgG1, BioLegend). Blood
was taken from experimental animals by tail vein bleeding 4 days
before and 4, 10, 14, 22 and 30 days after immunization and the
percentage of FoxP3+ cells was determined by flow cytometry.
Electrophysiogy was performed at the end of the experiment 28
days after immunization. Two independent experiments were
performed with 5–6 animals per group respectively.
Adoptive transfer neuritis in NOD-SCID mice
ICAM-1-/- NOD mice spontaneously develop a chronic
inflammatory neuropathy that can be adoptively transferred to
immunodeficient hosts by isolated CD4+ T cells [28]. Splenocytes
were purified from approximately one year old, clinically affected
ICAM-1-/- NOD mice. After 48h in culture, cells from all donor
animals were pooled, washed three times with PBS, adjusted to
236106 cells suspended in 400 ml PBS per animal and
intravenously injected into 6 to 8 weeks old host immunodeficient
severe combined immunodeficient (SCID) mice on NOD back-
ground (Taconic) subsequently named NOD-SCID mice. Recip-
ient mice were maintained under specific pathogen free conditions
for up to 10 weeks and were analyzed for phenotypic signs of
neuropathy twice per week by a blinded investigator (S.C.). Treg
depletion was performed by intraperitoneal antibody application
as described above on days 6 to 10 (early depletion) and days 37 to
40 (late depletion) after adoptive transfer. Electrophysiogy was
performed at the end of the experiment 50 and 70 days after
transfer in early and late depleted animals, respectively.
Grip strength analysis
The standardized grip strength test was performed for hind
limbs as previously described [29]. Briefly, mice were grasped at
the proximal base of their tail and pulled towards a horizontal T-
bar (width 12 cm, diameter 1.5 mm) connected to a gauge with
increasing force. The maximum force (measured in Newton)
exerted onto the T-bar before the animals lost grip was recorded.
Four measurements were performed at each observation day and
average values were calculated. To reduce the impact of learning
and training on the test results, grip strength was measured at days
14, 13, 12 and 6 before immunization and the relative change in
hind limb grip strength compared to average pre-immunization
values was calculated for further analysis.
Electrophysiology
Mouse sciatic nerve conduction properties were determined as
previously described [29]. Briefly, mice were anaesthetized using
intraperitoneal injection of ketamin (100 mg/kg) and xylazin
(5 mg/kg), while constant body temperature was maintained using
a heating plate connected to a rectal temperature sensor. Two
recording electrodes were inserted into the small foot muscles to
assess motor response. Two monopolar stimulating electrodes
were placed dorsal of the ankle and at the sciatic notch enclosing
the sciatic nerve for distal and proximal stimulation, respectively.
Stimulation was performed with increasing current until supra-
maximal stimulation was achieved. Maximum compound muscle
action potential (CMAP) amplitude voltage (mV) was recorded.
Nerve conduction velocity (NCV, m/s) was calculated as the
quotient between the distance and the difference of motor
latencies between proximal and distal stimulation. Average values
were calculated from two independent recordings per animal.
Tregs in Neuritis Models
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Histology
Animals were sacrificed by cervical dislocation and directly
intracardially perfused with phosphate buffered saline (PBS)
followed by 4% paraformaldehyde. Sciatic nerves were dissected,
paraffin embedded, cut into 7 mm sections on a standard
microtome and haematoxylin-eosin (HE) stained following stan-
dard protocols. For immunohistochemical staining, nerve sections
were incubated with anti-mouse CD3 antibody (ab5690, Abcam)
followed by a biotinylated goat anti-rabbit secondary antibody
(BA-1000, Vector) and a streptavidin-biotin-horseradish peroxi-
dase complex (DAKO). 3,39-diaminobenzidine (DAB) was added
as peroxidase substrate according to manufacturer’s instructions.
Between all protocol steps sections were washed for five minutes in
PBS. Slides were dehydrated and mounted in xylene based
medium (Merck). All incubations were performed at room
temperature. The entire sciatic nerve section was photographed
using a standard microscope (Zeiss) and photographs were
photomerged using Photohop CS3 (Adobe). The total endoneural
area was measured and the number of CD3 reactive cell nuclei
was counted on merged photographs of the sections by a blinded
investigator (S.C.) using the CellCounter plug-in of ImageJ (v143,
NIH). The density of CD3+ cells per mm2 section area was
calculated.
Cell preparation and flow cytometry
Splenocytes were extracted from dissected spleens by passing
through a 40 mm cell strainer followed by erythrocyte lysis (both
BD Biosciences). Splenocytes were either cultured (16107/well) in
6-well plates stimulated using soluble antibodies against CD3
(1 mg/ml, 145-2C11, from BD Pharmingen) and CD28 (0,5 mg/
ml [PV-1] from Abcam) at 37uC in a humidified CO2 incubator
for adoptive transfer, proliferation experiments or stained for flow
cytometry. Blood taken by tail vein bleeding was collected in 75 ml
hematocrit capillaries (Radiometer Clinical Aps) and transferred
into 1 ml of PBS/1%FCS/10 mM EDTA solution followed by
erythrocyte lysis. Flow cytometry was performed from blood and
spleen cells. Cells were stained for cell surface CD4 (L3T4, APC or
Pacific Blue labelled), CD25 (3C7, PE labelled) and intracellular
FoxP3 (MF23, Pacific Blue or APC labelled) using the FoxP3
staining buffer set (all from BD Biosciences). Flow cytometry was
performed using a FACSCanto II flow cytometer (BD Bioscienc-
es). To assess the autoimmune proliferatory response after Treg
depletion, splenocytes from NOD-SCID mice having previously
received adoptive transfer of ICAM-1-/- NOD lymphocytes and
injections of anti-CD25 antibodies were cultured in the presence of
syngenic mouse sciatic nerve homogenisate. 26105 splenocytes
were maintained in 96-well plates for 96 hours. 3H-Thymidin
(Hartmann Analytic) was added for the last 24 hours and
proliferation was assessed in quadruplicate wells by measuring
3H-Thymidine incorporation. Stimulatory indices were calculated
by dividing counts per minute (CPM) of each well by the average
CPM of non-stimulated wells.
Data acquisition and analysis
All flow cytometry data were analyzed using FlowJo software
(v7.2.5 TreeStar). Data were statistically analyzed using Graph-
PadPrism 5.0 (GraphPad Software). The Wilcoxon-Mann-Whit-
ney and Student’s t-test for unrelated samples were used to test for
statistically significant differences of non-Gaussian and Gaussian
distributed data, respectively. Differences were considered signif-
icant at p-values ,0.05.
Results
DTx mediated Treg depletion deteriorates EAN in DEREG
mice
We used different approaches to study the importance of Tregs
in EAN. The previously described DEREG mouse line expresses
the human DTx receptor under the control of the FoxP3
promotor together with a GFP reporter [24]. Expression of the
human DTx receptor confers toxin sensitivity to othwerwise toxin
resistant mouse cells and thus allows cell type specific Treg
depletion by DTx [24,30]. Intraperitoneal DTx application
successfully depleted FoxP3+ cells from the periphery as traced
by GFP expression and FoxP3 staining (Fig. 1A). DTx mediated
Treg depletion after EAN induction significantly increased the
severity of EAN symptoms (Fig. 1B). The average sciatic nerve
conduction velocity was significantly reduced in Treg depleted
DEREG mice compared to wildtype mice (Fig. 1C). As previously
described, active immunization – which is required for EAN
induction – triggers lethal toxicity of DTx independent of its Treg
depleting effect already in conventional C57BL/6 mice [31]. In
the current setting, clinical signs of EAN and DTx toxicity could
not be safely distinguished, preventing further detailed analyses of
Treg depletion during the course of EAN in DEREG mice.
Antibody mediated Treg depletion deteriorates EAN in
SJL mice
We therefore utilized anti-CD25 directed antibody mediated
Treg depletion as previously described in models of central
nervous system inflammatory demyelination [32]. Indeed, intra-
peritoneal applications of anti-CD25 antibody significantly
reduced the percentage of FoxP3+ cells in blood cells of SJL mice
(Fig. 2A). This strong reduction persisted for approximately three
weeks until Treg numbers increased again (Fig. 2B). Immuniza-
tion of SJL mice with bovine peripheral nerve myelin induced
EAN with little impairments (Fig. 3A). Application of CD25
antibody before immunization (day -4 to -1) increased peak EAN
severity (Fig. 3A). Antibody application at the peak of EAN
severity (day 14 to 17) did not alter the clinical score (Fig. 3A). In
addition to clinical scoring, we utilized hind limb grip strength as
quantitative measure of impairments in EAN. In accordance with
the clinical phenotype, hind limb grip strength decreased after
EAN induction (Fig. 3B). Treg depletion significantly increased
the strength loss associated with EAN induction, both when
applied before immunization and at the peak of disease (Fig. 3C).
Sciatic nerve conduction studies revealed a dispersion of
compound muscle action potentials and reduced nerve conduction
velocities in a proportion of animals having received early and late
Treg depletion (Fig. 3D). No abnormalities were detected in
control animals (Fig. 3D). Histology identified focal infiltration of
mononuclear cells in the sciatic nerve of Treg depleted mice with
EAN (Fig. 4A). CD3+ T cells could be observed at higher
frequencies in depleted animals (Fig. 4B). The density of CD3+ T
cells was increased in depleted animals and was highest in animals
after late Treg depletion (Fig. 4C).
Antibody mediated Treg depletion deteriorates
adoptively transferred neuritis
Murine EAN in our hands features low disease severity, making
clinical assessment difficult in this model. Also, the spontaneous
neuritis in ICAM-1 deficient (ICAM-1-/-) NOD mice is experi-
mentally difficult to utilize due to its highly variable onset [28]. To
circumvent these limitations, we adoptively transferred chronic
neuritis from ICAM-1-/- NOD mice into immunodeficient hosts
Tregs in Neuritis Models
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thus triggering neuritis with synchronized onset but at the same
time clinically resembling aspects of human chronic inflammatory
neuropathies. Again application of the CD25 antibody reduced
the percentage of FoxP3+ cells in NOD-SCID recipients. This
reduction exhibited a non-significant trend in early depleted
animals analyzed 40 days after depletion (Fig. 5A) and was
significant in late depleted animals 30 days after depletion
(Fig. 5B).
Adoptive transfer of ICAM-1-/- NOD lymphocytes into NOD-
SCID mice caused progressive impairments first manifesting 20
days after transfer (Fig. 6A). Early Treg depletion (days 7 to 10
after transfer) accelerated the manifestation of neuritis symptoms
and shortened the latency until recipient animals reached
moderate paraparesis (score 6) by 15 days in comparison to
controls (Fig. 6A). Animal experimentation was then terminated
for ethical reasons. Late depletion (days 37 to 40) did not alter the
clinical course of the adoptively transferred neuritis (Fig. 6A).
Electrophysiological abnormalities were more pronounced in early
depleted animals (Fig. 6B) and average nerve conduction velocities
were significantly lower in early depleted recipient mice (Fig. 6C).
We have previously demonstrated that ICAM-1-/- NOD mice
show autoreactivity against components of their peripheral nerve
myelin [28]. We here found, that lymphocytes from late depleted
animals showed greater lymphocyte proliferation reactivity against
sciatic nerve tissue than controls (Fig. 6D). In sciatic nerve paraffin
sections the density of cell nuclei did not differ between depleted
and non-depleted adoptive transfer recipients (Fig. 7A). The
frequency of CD3+ T cells was higher in depleted mice than in
controls (Fig. 7B). Quantification found an increased density of
CD3+ T cells after late Treg depletion (Fig. 7C).
Figure 1. Treg depletion in DEREG mice exacerbates EAN. (A) DEREG mice expressing the human diphtheria toxin (DTx) receptor under the
control of the FoxP3 promotor together with green fluorescent protein (GFP) reporter were injected with 50 mg/kg DTx (1 mg per mouse) on days 3
and 4 after immunization against myelin protein zero peptide P0180–199. Flow cytometry dot plots depict the CD4+ fraction of DEREG splenocytes
stained against FoxP3 and CD25 7 days after intraperitoneal PBS (left panels) or DTx (right panels) injection. (B) DEREG (n = 4) and control (n = 4) mice
were immunized with myelin protein peptide P0180–199 and received DTx injections on days 3 and 4 after immunization and daily clinical scoring was
performed until day 11 post immunization. (C) Sciatic nerve conduction velocity was assessed on day 11 after EAN induction in diphtheria toxin
treated wildtype (left bar) and DEREG mice (right bar). Plots depict mean 6 SEM in panels B and C. One representative out of two independent
experiments is depicted. DTx diphthteria toxin, wt wildtype, NCV nerve conduction velocity. * p,0.05.
doi:10.1371/journal.pone.0108756.g001
Figure 2. CD25 directed antibody continuously depletes Tregs. (A) SJL mice received intraperitoneal injections of CD25 directed antibody
(clone PC61) or isotype control. Flow cytometry contour plots depict blood mononuclear cells from isotype (left panel) and CD25 antibody (right
panel) treated animals stained for FoxP3 and CD4. (B) The percentage of FoxP3+ of blood CD4+ cells in isotype (black line) and CD25 antibody (red
line) treated animals at 4, 10, 14, 22 and 30 days after depletion was determined by flow cytometry. *** p,0.005.
doi:10.1371/journal.pone.0108756.g002
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Discussion
Tregs are indispensable for the maintenance of self tolerance
and immune homeostasis and Treg dysfunction has been
associated with various human autoimmune disorders and has
been discussed as one potential factor driving disease progression.
Reduced levels or an impaired function of Tregs have been
described in human patients with acute and chronic inflammatory
neuropathies. One study reported a transiently reduced number of
FoxP3+ Tregs during acute stages of GBS while their suppressive
function was unaltered [16]. Two technically less stringent studies
reported a reduction in CD4+CD25+ T cells, which may include
activated T effector cells in the acute phase of GBS without
studying FoxP3 expression [14,15]. In CIDP patients, one study
found a reduction in the proportion and suppressive function of
FoxP3+ Tregs [17], while another study reported an unchanged
proportion, but decreased suppressive function [33]. In animal
models, Tregs have been shown to be present in the PNS during
acute stage EAN [19] and that their numbers are reduced during
EAN [20]. Several studies reported an increase in Treg numbers
with treatments ameliorating EAN [21–23].
Previous studies have not addressed, however, if Tregs
functionally determine the manifestation of inflammatory neurop-
athies and if Treg numbers may represent a factor determining
chronicity of autoimmunity in the peripheral nerve. We here
demonstrate that depletion of Tregs increases the disease severity
of actively induced and adoptively transferred murine autoim-
mune neuritis models. We conclude that Tregs suppress autoin-
Figure 3. Treg depletion deteriorates active EAN in SJL mice. (A) Active EAN was induced by subcutaneous immunization with myelin protein
zero peptide P0180–199 in complete Freund’s adjuvant. Animals received intraperitoneal injections of CD25 antibody on days 4 to 1 before (early
depletion) and day 14 to 17 (late depletion) after immunization. Animals were regularly checked for impairments and a clinical score was assigned in
a blinded fashion. The mean score is depicted. (B) Hind limb grip strength was measured from day 14 before immunization onwards and the change
(D) in grip strength measured in Newton (N) relative to average pre-immunization values was calculated for each individual day. Values of isotype
treated controls compared to early and late depleted animals are depicted in the top and bottom panel, respectively. Plots depict mean 6 SEM in
panels B and C. One out of two independent experiments is shown. (D) Sciatic nerve electrophysiology was performed on day 28 after immunization
and representative measurements of individual animals are displayed. Individual early depleted animals (middle panel) presented
electrophysiological signs of demyelination such as prolonged distal motor latency (DML) and reduced compound muscle action potential (CMAP)
amplitudes. * p,0.05.
doi:10.1371/journal.pone.0108756.g003
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flammatory reactions in the PNS and determine disease severity in
inflammatory neuropathies. In synopsis with the previously
published descriptive studies in human neuritis patients and
corresponding animal models our findings are thus the first to
demonstrate a functional relevance of Tregs in peripheral neuritis.
Depletion had more pronounced effects if performed early in
the course of the respective disease model, indicating that Tregs
constrain inflammation during the priming phase of EAN and
during the early phases of adoptively transferred neuritis. Although
Tregs are required to prevent autoimmunity throughout the
lifespan of mice [30], reducing their numbers does not increase the
severity of neuritis if disease has already manifested. Our findings
thus do not support the hypothesis that Tregs determine whether
autoimmunity in the PNS remains acute and monophasic as in
GBS or chonically progressive as in CIDP. There are no data
available to determine whether Tregs take effect in the periphery
or locally in the PNS but our data may indicate that the early
priming phase in the periphery is the more important site of action
for Tregs in inflammatory neuropathies.
Our analysis of Tregs was impeded by several methodical
difficulties. Firstly, when establishing the DEREG mouse model,
we found that DTx could not be combined with active
immunization of any kind due to a non-cell type specific probably
septic reaction [31]. Therefore, analyses in this model had to
remain limited. The model especially did not allow to differentiate
between toxic and paretic symptoms making clinical scoring
inadaequate. This is why we used CD25 directed antibodies for
the depletion of Tregs. This is – naturally – less specific, but has
provided crucial insights in the pathophysiological relevance of
Treg previously. In accordance with previous studies in experi-
mental autoimmune encephalomyelitis (EAE) [27,32] we could
still demonstrate successful and prolonged reduction of Treg
numbers following CD25 antibody treatment supporting the
adeaquacy of our approach.
Initially EAN was established in different non-murine species
and preferentially used in the Lewis rat strain [34]. More recently,
EAN induction has been described in different mouse strains [35–
37]. In contrast to these published studies, however, we and others
(Ralf Linker, University of Erlangen, personal communication)
have repeatedly failed to induce severe and thus clinically well
traceable EAN in mice. We used a bovine peripheral nerve myelin
induced EAN in SJL mice, which in our experience features the
greatest disease severity and reliability [36]. We further attempted
to circumvent the low disease severity by using quantitative hind
limb grip strength assessment as improved measure of paresis.
Referential values in comparison to pre-immunization grip
strength allowed to exclude learning and training effects. Here,
we found an increased EAN severity following Treg depletion.
Still, the effect of Treg depletion was less pronounced than
expected. Previous investigations on the role of Treg were mainly
performed by using depleting anti-CD25 antibodies. As a
limitation, one has to consider that CD25 is also up-regulated
on activated T cells [38] and there is evidence for a CD25-
negative Treg subpopulation, which is not depleted [39].
We additionally used an adoptive transfer paradigm to elicit a
severe progressive autoimmune neuropathy previously described
in ICAM-1-/- NOD mice [28]. Using a defined donor cell pool, we
ensured that all animals received equal amounts of neuritogenic
cells and that the resulting neuritis thus features a defined onset
and severity. Early, but again not late, Treg depletion increased
disease severity in this transfer model. This contrasts with the
finding that Treg numbers were not reduced and PNS myelin
directed autoreactivity was not increased in early depleted animals.
The interval between depletion and flow cytometric and
Figure 4. Treg depletion increases PNS T cell infiltration in active EAN. (A) Randomly chosen animals from all groups were sacrificed at day
15 post immunization and sciatic nerve paraffin sections stained with haematoxyllin-eosin demonstrates infiltration of mononuclear cells (arrows) in
early (middle panel) and late (right panel) depleted animals. (B) Sciatic nerve sections were stained against CD3. Depleted animals had a higher
frequency of CD3+ T cells. (C) The number of CD3+ T cells was manually counted and the relative cell density was quantified. The density of CD3+
cells was significantly higher in late depleted animals. Scale bars depict 50 mm in panels A and B. * p,0.05.
doi:10.1371/journal.pone.0108756.g004
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proliferation analysis was 10 days greater in early than in late
depleted animals explaining the discrepancy. Of note, myelin
auto-reactivity increased in late depleted animals, but was
insufficient to further deteriorate the developing neuropathy.
One may speculate that the speed of development of neuropathy
cannot accelerate further after its onset. It remains to be
determined if Tregs could actively inhibit neuritis if induced at
this time point.
In conclusion, we have demonstrated the functional relevance of
Tregs for the manifestation and severity of inflammatory
Figure 5. CD25 directed antibody depletes Tregs and increases myelin autoreactivity in adoptive transfer neuritis. (A) Lymphocytes
from ICAM-1-/- NOD mice were adoptively transferred into immunodeficient NOD-SCID mice. Recipients received intraperitoneal injections of isotype
control (left panel) or CD25 antibody (middle panel) and the proportion of FoxP3+ spleen cells was assessed by flow cytometry. On day 50 after
transfer – 40 days after early depletion – the percentage of FoxP3+ cells in early depleted animals showed a non-significant trend towards reduction
(right panel). (B) On day 70 after transfer – 30 days after late depletion – the percentage of FoxP3+ cells was analyzed by flow cytometry and
significantly reduced in late depleted animals. Box plots depict mean 6 SEM in all panels. ns non significant, iso isotype control, ** p,0.01.
doi:10.1371/journal.pone.0108756.g005
Figure 6. Treg depletion deteriorates adoptive transfer neuritis. (A) Following adoptive transfer of lymphocytes from ICAM-1-/- NOD into
immunodeficient NOD-SCID mice, recipients received intraperitoneal injections of CD25 antibody between day 7 and 10 (early depletion) or between
day 37 and 40 (late depletion) after transfer. Clinical scoring was performed in a blinded fashion. (B) Sciatic nerve electrophysiology was performed
when terminating the early (top panel) and late (lowel panel) depletion experiment at 45 and 70 days after transfer, respectively. (C) The average
nerve conduction velocity (NCV) in all experimental groups was calclulated. Plots depict mean 6 SEM in panels A and C. iso isotype control. (D)
Lymphocytes extracted from adoptive transfer recipient mice were restimulated in culture with sciatic nerve homogenisates and T cell proliferation
was measured by 3H-Thymidin incorporation in quadruplicate wells. Stimulation indices were calculated as multiple of unstimulated wells.
doi:10.1371/journal.pone.0108756.g006
Tregs in Neuritis Models
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e108756
neuropathies. In synopsis with previous descriptive human data,
this identifies Tregs as potential therapeutic target in the early
stage of disabling inflammatory neuropathies.
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